Vaxcyte, Inc.

NASDAQ:PCVX

Biotechnology

Healthcare
$58.52 +3.83%

+$1.94 today

Market cap
$9.26B
Beta
1.24
P/E (TTM)
-7.8
EPS (TTM)
-$6.78
52W Low $29.08High $65.00

Volume 1.13M

Average 1.44M

PCVX Debt Repayment

Cash used to repay borrowings during the period.

Vaxcyte, Inc.NASDAQ: PCVX

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment outflow grows to $0

Q2 FY2026 debt repayment was $0, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $0.

Context

  • Debt repayment increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Debt Repayment vs competitors

How PCVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
PCVX Competitors
Debt Repayment for PCVX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$3.54B USD+17775.0%—140.0%
PFEPfizer Inc.LTM Jun 2026$1.78B USD+121.9%-72.4%2.8%
GSKGSK plcLTM Jun 2026£998.88M GBP+753.7%—3.0%
NVAXNovavax, Inc.LTM Mar 2026$80.57M USD+1480.8%-26.4%13.5%
IBRXImmunityBio, Inc.LTM Sep 2026$5.95M USD+12297.9%-78.5%3.3%
VALNValneva SELTM Mar 2026€760.99K EUR+113.7%-87.9%0.5%
VIRVir Biotechnology, Inc.LTM Mar 2026$361K USD+276.0%+11.6%0.6%
PCVXVaxcyte, Inc.LTM Jun 2026$0 USD———
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding PCVX) —+514.9%-72.4%2.9%

Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(100.08M)(223.49M)(402.27M)(463.93M)(766.63M)
Depreciation & Amortization3.46M9.45M10.17M15.85M24.86M
Deferred Income Tax00000
Stock-Based Compensation10.73M23.65M48.76M84.82M138.85M
Change in Working Capital(37.01M)12.74M81.32M(54.9M)(3.45M)
Accounts Receivables00000
Inventory00000
Accounts Payables(12.47M)2.9M11.23M34.58M19.91M
Other Working Capital(24.54M)9.84M70.1M(89.48M)(23.36M)
Other Non-Cash Items1.5M7.05M(34.78M)(34.47M)(49.2M)
Operating Cash Flow(121.39M)(170.6M)(296.79M)(452.63M)(655.58M)
Capital Expenditures(6.56M)(5.84M)(67.88M)(22.43M)(13.71M)
Acquisitions (Net)00000
Purchases of Investments(336.34M)(102.75M)(1.33B)(3.09B)(1.21B)
Sales of Investments130.56M183.17M624.46M1.2B1.71B
Other Investing Activities26K00(96.73M)(43.26M)
Investing Cash Flow(212.31M)74.59M(773.31M)(2.01B)437.35M
Debt Repayment00000
Common Stock Issued13.9M856.48M636.04M2.44B13.01M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.9M5.07M3.77M12.85M(10.99M)
Financing Cash Flow17.8M861.55M639.81M2.45B2.01M
Effect of Forex Changes(439K)137K(6.69M)426K2.44M
Net Change in Cash(316.34M)765.67M(436.97M)(9.36M)(213.77M)
Free Cash Flow(127.95M)(176.44M)(364.67M)(475.05M)(669.29M)

Vaxcyte, Inc.

NASDAQ:PCVX

Intrinsic Alpha fair value

Locked

Current Price

$58.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.